WEDNESDAY, Jan. 23 (HealthDay News) -- Exjade (deferasirox) has been approved by the U.S. Food and Drug Administration to remove excess iron in the blood among people with a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT).
Too much iron in the blood can damage vital organs, the agency said Wednesday in a news release.
Thalassemia typically leads to the production of fewer red blood cells and less hemoglobin, a protein that carries oxygen throughout the body. NTDT is a milder form of thalassemia that unlike other forms, does not require frequent blood transfusions. Thalassemia affects about 1,000 people in the United States, the FDA said.
The FDA previously approved Exjade to treat chronic iron overload among people who require blood transfusions.
The drug is produced by Novartis, East Hanover, N.J.
The U.S. National Heart Lung and Blood Institute has more about thalassemia.
be well, feel better
Experience more joy every day with these surprising new scientifically proven tactics.
Sunscreen strategies and formulas to help protect even the most sensitive skin from sun damage and cancer.
Get the facts on staying healthy and comfortable when the temperature rises.
Trick your brain into doing what you want it to do.
Which are just gross, and which are truly dangerous?
Plus, tips from experts on ways to drop those excess pounds
How to use color therapy to feel better.
Banish stress and enjoy a greater sense of balance in your life.